GSK2330672 is an inhibitor of the ileal bile acid transporter, designed to have minimal systemic exposure, and is under development as a potential therapeutic for pruritus associated with primary biliary cholangitis and other cholestatic liver diseases. A phase 1, double-blind, placebo-controlled, 4-period crossover study was conducted to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of GSK2330672 in healthy Japanese participants. Sixteen healthy male participants received single oral doses of GSK2330672 (10-180 mg) or placebo in each period. No serious adverse events and no adverse events leading to study discontinuation or withdrawal were reported. Drug-related adverse events reported included gastrointestinal symptoms (mostly diarrhea) and positive fecal occult blood tests, and were all mild and resolved without any interventions. GSK2330672 was undetectable in the majority of participants' plasma. Pharmacodynamic observations included a tendency for total serum bile acids to reduce and for serum 7α-hydroxy-4-cholesten-3-one, a key intermediate of bile acid synthesis, to increase with increasing doses of GSK2330672. In the context of recently published indications of potential efficacy for cholestatic pruritus in non-Japanese populations, these data support further evaluations of GSK2330672 in Japanese patients.
ileal negative feedback regulation of hepatic bile acid synthesis. 12, 13 Given that elevated ileal bile acid absorption is described in cholestatic liver disease, 14, 15 it has been postulated that an IBAT inhibitor may potentially suppress bile acid reabsorption and shunt the unabsorbed bile acids down the gastrointestinal tract and hence be a new therapeutic strategy for the treatment of PBC and associated symptoms including pruritus.
Among multiple IBAT inhibitors reported to date, [16] [17] [18] [19] [20] [21] GSK2330672 is a potent, soluble, selective inhibitor of human IBAT. This compound was selected because of its ability to engage the IBAT on the luminal surface of the gastrointestinal tract with minimal absorption, limiting intestinal and hepatic first pass metabolism and minimizing systemic exposure. The compound has a potency of IC 50 = 42 ± 3 nM (mean ± standard error) in HEK293 cells expressing human IBAT. Its cellular permeability is low (P app = 7 nm/s) in MDR1-MDCK cells. When a single oral dose (10 mg/kg) was tested in Sprague-Dawly rats, its maximum portal vein and systemic blood concentrations (C max ) were low (4 ng/mL and actually zero, respectively), with stable levels in the intestine and nearly complete recovery in feces. 20 The compound was assessed in animal models of type 2 diabetes mellitus and humans with type 2 diabetes mellitus. 20, 21 The compound was also assessed in healthy non-Japanese volunteers with a favorable tolerability and safety profile in two phase 1 studies (BAT114985 [NCT01416324]; firstin-human study of GSK2330672 22 and BSC116511 [NCT01607385]: unpublished data). A phase 2a, randomized, double-blind, placebo-controlled, crossover study (NCT01899703) was recently conducted in patients with PBC manifesting pruritus, in which 14-day treatment with GSK2330672 was associated with no serious adverse events and improved itch symptoms as measured by a patient-reported 0 to 10 numerical rating scale. 23 In addition, these studies showed the compound to decrease the serum levels of total bile acids and concomitantly increase 7α-hydroxy-4-cholesten-3-one (C4), a key intermediate of bile acid synthesis, suggesting engagement of the pharmacodynamic (PD) mechanism. 22, 23 Furthermore, in vitro experiments showed that GSK2330672 does not inhibit CYPs 1A2, 2C19, 2D6 or 3A4 at concentrations up to 33 μM, but is a weak inhibitor of organic anion transporting polypeptide 1B1 (OATP1B1, IC 50 value of 13 μM) and breast cancer resistance protein (27% inhibition at 300 μM). The compound does not inhibit P-glycoprotein at concentrations up to 300 μM and is inactive in human Pregnane X receptor reporter gene assay (unpublished results). Given the information above, the risk for clinically significant interactions of GSK2330672 with other drugs is deemed to be low.
We therefore evaluated the safety, tolerability, and pharmacokinetic (PK) and PD parameters following single doses of GSK2330672 in healthy Japanese males in a randomized, double-blind, placebo-controlled crossover study (NCT02801981). This was the first use of GSK2330672 in a Japanese population.
Participants and Methods Ethics
This study was conducted between June 20 and August 5, 2016, at Keikokai Medical Corp. P-One Clinic (Hachioji, Tokyo) in line with the 2013 Declaration of Helsinki and in accordance with the principles of the International Conference on Harmonisation Good Clinical Practice. The study protocol and other relevant documents were reviewed and approved by the Institutional Review Board of the study site. Written informed consent was obtained from all participants prior to the study start.
Study Design and Population
This was a phase 1 study of a randomized, doubleblind, dose-escalating, placebo-controlled, 4-period, crossover design. GSK2330672 was administered to 12 participants as a single dose per period in a dose-escalating manner from 10 up to 180 mg, while placebo was administered to 4 participants per period. GSK2330672 was formulated as 10 mg and 45 mg of white-to-slightly colored, round, film-coated tablets, which were visually indistinguishable from matching placebo tablets.
For each period, participants were admitted to the study site on the evening of Day -1 (prior to dinner). On the next morning (Day 1), they received either GSK2330672 or placebo half an hour prior to breakfast, and underwent preset tests and examinations during 48 hours postdose including 24.5-hour PK and PD measurements (see the Blood Sample Collection and Bioanalytical Methods section). The participants were released from the site on Day 3. A washout of at least 6 days was set between the 2 neighboring doses of study drug. Dose escalation was made according to safety assessments (see below) in individual participants during each treatment period.
Healthy Japanese males aged between 20 and 64 years with body mass index of ࣙ18.5 kg/m 2 to <25.0 kg/m 2 were eligible for study participation. Volunteers were excluded if they had alanine aminotransferase and/or bilirubin levels >1.5× the upper limit of normal (40 IU/L and 20.52 μmol/L, respectively), if they had a current or chronic history of hepatic disease, diarrhea-causing diseases, or positive blood tests for hepatitis B, hepatitis C, HIV, or human T-lymphotropic virus type 1. The concomitant use of medications, vitamins, dietary or herbal supplements, or any nondrug therapies was not allowed from 14 days before the first dose of the study drug to the completion of followup examinations, except if emergency treatments were required at an investigator/subinvestigator's discretion.
Safety Assessments
Adverse events were collected from immediately after the first dose of study drug until 7 days after the last dose. Laboratory tests (blood chemistry, hematology, and urinalysis) were performed at screening, on Day -1, at 48 hours postdose, and at the 7-day follow-up visit. Physical examinations were performed at screening, on Day -1, predose, at 2, 12.5, 24.5, and 48 hours postdose, and at the 7-day follow-up visit. Vital signs and 12-lead electrocardiogram were measured on the same schedule except for predose measurement. Participants were also tested for fecal occult blood at screening and once in each dosing period. If positive, the participant repeated the test before the next dose.
Blood Sample Collection and Bioanalytical Methods
Blood samples for plasma GSK2330672 determination were taken from participants predose in each period and at 0.5 hours (immediately prior to breakfast), at 2 and 3.5 hours (immediately prior to lunch), and at 5 hours postdose. One milliliter of blood was collected into an EDTA-2K tube and centrifuged at 1700 × g for 10 minutes at 4°C. The resulting plasma was transferred into a polypropylene tube and stored at -20°C until shipment. Plasma samples were shipped frozen on dry ice to Covance bioanalytical facilities (Madison, Wisconsin). Plasma concentrations of GSK2330672 were analyzed by LC-MS/MS (API 4000; Sciex, Framingham, Massachusetts). Briefly, GSK2330672 was extracted from a 0.05 mL of plasma by protein precipitation using 0.15 mL of acetonitrile containing an isotopically labeled internal standard (IS),
The extract was applied to ACQUITY UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm; Waters, Milford, Massachusetts) at room temperature and eluted with an equal volume of 0.1% formic acid and 0.1% formic acid in acetonitrile at 0.4 mL/min. The eluent was introduced via electrospray ionization using a TurboIonSpray interface in positive ion mode. Multiple reaction monitoring was employed, and transmission masses for GSK2330672 and the IS were 547 to 224 and 552 to 224, respectively. The lower limit of quantification (LLQ) was 1 ng/mL and the upper limit of quantification was 1000 ng/mL.
Blood samples for PD analysis (serum bile acids and C4) were also collected predose and until 24.5 hours postdose. Blood sampling at 0.5, 3.5, 9.5 and 24.5 hours postdose was performed immediately prior to meals. Five milliliters of blood collected in a serum separator tube was allowed to stand for 30-40 minutes for clotting, and then centrifuged at 1700 × g for 15 minutes. One milliliter and 0.7-mL aliquots of serum were transferred into polypropylene tubes and stored at -20°C and -70°C until shipment for the assay of total bile acids and C4, respectively. Following shipment on dry ice, serum bile acids were assayed at Quest Diagnostics Nichols Institute (Valencia, California) based on the enzyme cycling method using Diazyme's total bile acids assay kit on a throughput workstation (Beckman Olympus AU2700). The verified assay range was 0.8-180 μmol/L. C4 was assayed at Q2 Solutions (Ithaca, New York) by LC-MS/MS (API6500, Sciex, Framingham, Massachusetts). Briefly, 0.04 mL of serum containing isotopically labeled IS, [ 2 H 7 ]-C4 was placed onto ISOLUTE SLE+ cartridge (400 μL; Biotage, Charlotte, North Carolina). C4 was extracted twice with 0.9 mL of chloroform. Following evaporation, the residue was derivatized in 2-picolinic acid, 2-methyl-6-nitrobenzoic anhydride and 4-dimethylamino pyridine for 30 minutes. The product was mixed with hexane including 5% sodium bicarbonate and centrifuged. After evaporation of the upper layer, the dried residue was reconstituted with 0.1 mL of acetonitrile/water (90:10 by volume) and analyzed using ACQUITY UPLC BEH Phenyl column (2.1 × 100 mm, 1.7 μm; Waters) at 0.5 mL/min at 40°C with an appropriate gradient of 5 mM ammonium bicarbonate/acetonitrile (80:20 by volume) and acetonitrile. The eluent was then introduced via an atmospheric pressure chemical ionization interface in positive ion mode. Transmission masses for C4 and the IS were 506 to 124 and 513 to 124, respectively. The LLQ was 2 ng/mL and the upper limit of quantification was 250 ng/mL.
The intra-and interassay bias and precision for both GSK2330672 and C4 were less than 20% except for the LLQ, for which less than 25% was acceptable.
Statistical Methods and Data Analysis
Statistical power and sample size were not calculated formally for this study. Given that the BAT114985 study was conducted in 17 healthy participants (6 to 8 per dose group), showing no clinically meaningful safety findings but significant changes in PD parameters (ie, an increase in serum bile acids and a decrease in serum C4) in GSK2330672 groups compared to placebo treatment, 22 a size of 12 to 16 healthy Japanese participants per dose was deemed reasonable for the evaluation of the compound in the present study.
The safety, PK, and PD populations were all defined as all participants who received at least 1 dose of the study drug. Adverse events, changes in laboratory values, electrocardiograms, vital signs, and fecal occult blood tests were summarized by dose group. No formal statistical comparisons were made for the safety data. Plasma concentrations of GSK2330672 were summarized by dose group and nominal sampling time, but PK parameters were not calculated due to mostly undetectable concentrations of the compound.
Mean concentration-time profiles of serum bile acids and C4 were also summarized by dose group and nominal sampling time. Areas under the concentration-time curve (AUCs) of serum bile acids and C4 were calculated using Phoenix WinNonlin (version 6.3). Doseresponse analysis of weighted mean AUCs of serum bile acids and C4 was performed using an E max model, and predicted responses of weighted mean AUCs and their 95% confidence intervals were calculated at each dose from the fitted model. The following non-linear mixed effect model, 3-parameter E max model, was fitted for the weighted mean AUCs: PD ij = E 0 + (E max Dose ij )/(Dose ij + ED 50 ) + δ i +ε ij , where subscripts i and j denote i-th subject in j-th dose group. PD ij represents the value of weighted mean AUC for subject i at dose j, and E 0 is for response at dose 0 (placebo), E max for maximum effect as E max ࣘ0 for reduction and E max ࣙ0 for increase, ED 50 for dose at which 50% of maximum effect is reached, δ i for subject effect following N (0, σ b 2 ) and ε ij for residual error following N(0, σ 2 ). All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, North Carolina).
Results

Summary Demographics of Study Participants
A total of 62 Japanese male volunteers were screened, and 16 participants were equally randomized to any of the 4 treatment sequences. Reasons for screening failure were that the target number of participants was reached prior to the enrollment (n = 37), there was a deviation from the selection criteria (n = 6), and consent was withdrawn (n = 3). Demographic characteristics of study participants are summarized in Table 1 . All 16 participants were Japanese of East Asian heritage and completed the entire study. No important protocol deviations were reported throughout the study duration.
All participants were subjected to safety, PK, and PD analyses.
Safety and Tolerability
Adverse events were reported in 13 of 16 participants, and were judged study drug related except for 2 events (anal hemorrhage and blood creatine phosphokinase increased). As summarized in Table 2 , gastrointestinal disorders related to GSK2330672 treatment included diarrhea (27 events in 12 participants) and abdominal pain, and their incidence increased with dose. Fecal occult blood positive occurred in 4 participants following the treatment with placebo or GSK2330672 (30 and 90 mg), and all resolved within 2 days, with the second test results negative. Overall, the drug-related adverse events were mild in severity and resolved during the study with no specific measures taken.
No clinically meaningful, treatment-related findings were observed in clinical laboratory tests, vital signs, or 12-lead electrocardiogram tests during the study. No serious adverse events or adverse events leading to discontinuation or withdrawal from the study were reported.
Pharmacokinetics
GSK2330672 was mostly undetectable (lower than LLQ = 1.00 ng/mL) in plasma throughout the study. Two of 16 participants were the exceptions, showing plasma levels of the compound above LLQ at 2 and 3.5 hours following 30-, 90-, and 180-mg doses (1.20-6.64 ng/mL), and at 0.5 hours following a 180-mg dose (1.05 ng/mL), respectively.
Pharmacodynamics
Serum levels of total bile acids were profiled following GSK2330672 treatment in Figure 1 .
Although 95% confidence intervals were large at each time point for each dose, the serum levels of total bile acids tended to decrease with dose. The decrease was remarkable after lunch between 3.5 and 9.5 hours postdose except for the 30-mg dose. Despite a large interparticipant variability, the weighted mean AUC 0-24.5h (±SE) of total bile acids decreased gradually with GSK2330672 dose up to 180 mg (Figure 2 ), as summarized as 5.52 ± 1.240 for placebo, 5.01 ± 1.205 for 10 mg, 4.37 ± 1.269 for 30 mg, 3.57 ± 1.193 for 90 mg, and 3.15 ± 1.266 μmol/L for 180 mg with statistical significance (p<0.05) for 90-and 180-mg doses vs. placebo. E max model fitting analysis gave parameters (±SE) as E 0 = 5.52 (±1.240), ED 50 = 48.97 (±87.247) and E max = -3.01 (±1.394).
C4, a key intermediate of bile acid synthesis, was also determined post-treatment in the participants' sera. As profiled in Figure 3 , the levels of C4 tended to increase with GSK2330672 dose despite large 95% confidence intervals observed at each time point for each dose. This tendency was remarkable after meals (lunch as well as dinner). Though largely variable among participants, the weighted mean AUC 0-24.5h of C4 increased in a dose-dependent manner (20.21 ± 4.121 for placebo, 23.25 ± 3.934 for 10 mg, 28.33 ± 4.066 for 30 mg, 38.61 ± 4.120 for 90 mg and 47.14 ± 4.390 ng/mL for 180 mg) with statistical significance (P < .05) for all doses vs placebo ( Figure 4 ). E max model fitting analysis gave parameters (±SE) as E 0 = 20.21 (±4.121), ED 50 = 155.44 (±118.839) and E max = 50.18 (±19.041).
Discussion
The primary objective of this study was to evaluate the safety and tolerability of single oral doses of GSK2330672 when administered to a healthy Japanese population. No serious adverse events and no adverse events leading to study discontinuation or withdrawal were reported. Nonserious adverse events were reported in 13 of 16 participants during the study period and all but 2 events were judged study drug related. Gastrointestinal disorders were among the most frequent conditions reported, with diarrhea observed in 12 of 16 participants. This result was most likely due to an increased delivery of bile acids to the colon as a consequence of IBAT inhibition by GSK2330672, and was in line with the results recently observed in non-Japanese phase 1 22 and phase 2a studies with the compound. 21, 23 In relation, increased fecal bile acid excretion was reported in the non-Japanese phase 1 study (>2-fold compared to placebo treatment) 22 and not repeated in the present study. Similarly, changes in bowel habit were observed in non-Japanese studies, as indicated by worsened stool form rating and consistent with the known effects of increased colonic bile acids. 21, 22 While drug-related adverse events occurred more frequently at higher doses, all adverse events were mild and did not require any interventions for resolution. Drug-related fecal occult blood positivity was reported in 4 participants, including 1 who received placebo. The frequency of the event did not increase with increasing dose. Overall, the safety results obtained in the present study were comparable with those previously observed in non-Japanese clinical studies with GSK2330672. Thus, the safety data obtained following single doses of GSK2330672 support further evaluations of the compound in a larger-sized Japanese population.
Since the pharmacologic target of GSK2330672 is the enterocyte brush border in the intestinal lumen, the compound was structurally designed to have low permeability and high polar surface area to limit its absorption into the portal and systemic circulation. 20 As expected, GSK2330672 was not detected (below LLQ) in plasma of a majority of participants in the present study. Two participants showed transiently measurable, but not clinically significant, plasma levels of the compound. Similar PK characteristics were observed in non-Japanese phase 1 study 22 and phase 2a study in which patients with PBC with pruritus were treated with repeated doses of the compound (45 and 90 mg twice daily). 23 Among the phase 2a patients who showed transiently measurable plasma GSK2330672 levels, 1 patient achieved a peak plasma concentration (5.33 ng/mL) at 2 hours postdose, which was comparable to that observed in the present study. It is possible that the minimal systemic absorption could limit the toxicity spectrum of GSK2330672 and its potential interactions with other drugs in humans. This favorable profile supports further evaluations of the drug in a Japanese population.
We determined C4 and total bile acids in participants' sera. A tendency for total bile acids to reduce and C4 to increase was seen with increasing doses of the compound. The results were in line with those observed in non-Japanese studies. These PD results are consistent with C4 synthesis from cholesterol by hepatic CYP7A1, whose expression and activity is suppressed by bile acids. 24, 25 The present study was conducted as the first use of GSK2330672 in a Japanese population, albeit only single doses administered to a small population of male participants. PBC is more prevalent in women than in men, 1, 26 and hence further studies will establish the safety and efficacy of repeated doses of the compound in a larger population including female participants. For this purpose, a double-blind, multidose, placebo-controlled, 5-arm phase 2 study of GSK2330672 (NCT02966834) is ongoing for the treatment of pruritus in male and female patients with PBC.
